CD34 and myeloid sarcoma: Similarly, despite the complete arrest of MS disease activity post-AHSCT in the 2016 Atkins et al. trial (33), the use of a high-intensity myeloablative regimen makes it difficult to draw conclusions about the additional benefit of CD34+ selection.